AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $23M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$23M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 2 added, 3 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $231.60
- 52-wk high
- $266.38
- High
- $236.00
- 52-wk low
- $128.80
- Low
- $230.39
- Prev close
- $232.35
- Mkt cap
- $15.08B
- P/E
- 16.3x
- Volume
- 1.00M
- Fwd P/E
- 10.9x
- Beta
- 0.36
- P/S
- 3.3x
- P/B
- 3.3x
- Profit margin
- +20.4%
- Op margin
- +26.9%
- ROE
- +22.1%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about JAZZ filings
Are insiders buying or selling Jazz Pharmaceuticals PLC (JAZZ) stock?
Net selling: insiders sold $23M and bought $0 of JAZZ stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $23M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Iannone, Robert (EVP, Global Head of R&D & CMO), who sold $19.2M. The latest filing was on Sep 14, 2026.
Which members of Congress have traded JAZZ recently?
None. No member of Congress disclosed a JAZZ trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this JAZZ smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- TS
Two Sigma
$92.7M
added
Sells/Trims (2)
- P7
Point72
$67.8M
sold
- DS
D.E. Shaw
$35.4M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in JAZZ right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 3.4% below what analysts expected.
Earnings per share
$5.06 expected
Reports Nov 4, 2026, in 34 days
Estimates as of Oct 1, 2026
EPS expected
$5.81 to $7.11
Revenue expected
16 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.13B | $1.20B | $1.07B | $1.21B |
| Cost of what it sold | $257.8M | $24.6M | $306.4M | $116.4M |
| Gross profit | $868.3M | $1.17B | $762.5M | $1.09B |
| What it spent | ||||
| Research and development | $240.7M | $171.4M | $134.1M | $207.5M |
| Sales and admin | $530.6M | $406.2M | $352.7M | $389.2M |
| Other operating costs | $39.5M | -$313.5M | $61.9M | $247.0M |
| Total operating expenses | $810.8M | $264.1M | $548.7M | $843.7M |
| What was left | ||||
| Operating profit | $57.5M | $909.2M | $213.8M | $248.2M |
| Interest on debt | $48.6M | $45.4M | $63.3M | $37.1M |
| Profit before tax | $9.0M | $208.3M | $299.2M | $211.0M |
| Tax | -$242.4M | $4.9M | $6.1M | $18.1M |
| Net profit | $251.4M | $203.5M | $293.1M | $192.8M |
| EBITDA | $235.9M | $278.6M | $543.9M | $418.1M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
NeutralSep 30Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE)
BullishSep 30Citigroup Initiates Jazz Pharmaceuticals at Buy With $325 Price Target
BullishSep 30Jazz Pharmaceuticals stock reports record Q2 revenue growth
BullishSep 24Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.com
BullishSep 24Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and Recommendations
BullishSep 24Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033
BullishSep 23Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins.
Leans bullishSep 23
Macro
10 macro signals shaping JAZZ right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results